share_log

賽生藥業：根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

香港交易所 ·  Apr 8 17:15
Summary by Futu AI
赛生药业控股有限公司於2024年4月8日公布，其私有化交易已經進行。根據香港《公司收購及合併守則》規則22，CICC Wealth Investment Limited於2024年4月2日完成了與赛生药业有關的衍生工具合約清結交易。該交易包括兩筆合約，每筆合約均涉及167,500股，第一筆合約的參考價為每股$17.7753，總金額為$2,977,370.62；第二筆合約的參考價為每股$17.7715，總金額為$2,976,729.60。交易後，CICC Wealth Investment Limited持有的赛生药业股份數量為零。CICC Wealth Investment Limited是中國國際金融股份有限公司的子公司，並與赛生药业的要約人有關連。本次披露取代了原先於2024年4月3日的披露表格。
赛生药业控股有限公司於2024年4月8日公布，其私有化交易已經進行。根據香港《公司收購及合併守則》規則22，CICC Wealth Investment Limited於2024年4月2日完成了與赛生药业有關的衍生工具合約清結交易。該交易包括兩筆合約，每筆合約均涉及167,500股，第一筆合約的參考價為每股$17.7753，總金額為$2,977,370.62；第二筆合約的參考價為每股$17.7715，總金額為$2,976,729.60。交易後，CICC Wealth Investment Limited持有的赛生药业股份數量為零。CICC Wealth Investment Limited是中國國際金融股份有限公司的子公司，並與赛生药业的要約人有關連。本次披露取代了原先於2024年4月3日的披露表格。
Sai Seng Pharmaceutical Holdings Limited announced on 8 April 2024 that its privatization transaction has been completed. Pursuant to Rule 22 of the Hong Kong Code of Companies Acquisitions and Mergers, CICC Wealth Investment Limited completed on 2 April 2024 the liquidation of derivatives contracts related to the pharmaceutical industry. The transaction consists of two contracts involving 167,500 shares each; the first contract has a reference price of $17.7753 per share for a total amount of $2,977,370.62; the second contract has a reference price of $17.7715 per share for a total amount of $2,976,729.60. Following the transaction, CICC Wealth Investment Limited held by CICC Wealth Investment Limited was zero. CICC Wealth Investment Limited is a subsidiary of China International Financial Corporation and is associated with the underwriters of Sai Sai Sang Pharmaceuticals. This disclosure replaces the previous disclosure form dated April 3, 2024.
Sai Seng Pharmaceutical Holdings Limited announced on 8 April 2024 that its privatization transaction has been completed. Pursuant to Rule 22 of the Hong Kong Code of Companies Acquisitions and Mergers, CICC Wealth Investment Limited completed on 2 April 2024 the liquidation of derivatives contracts related to the pharmaceutical industry. The transaction consists of two contracts involving 167,500 shares each; the first contract has a reference price of $17.7753 per share for a total amount of $2,977,370.62; the second contract has a reference price of $17.7715 per share for a total amount of $2,976,729.60. Following the transaction, CICC Wealth Investment Limited held by CICC Wealth Investment Limited was zero. CICC Wealth Investment Limited is a subsidiary of China International Financial Corporation and is associated with the underwriters of Sai Sai Sang Pharmaceuticals. This disclosure replaces the previous disclosure form dated April 3, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.